In the future, we will continue to focus on the regulatory mechanism of TRIM21 in NKAPL and develop NKAPL methylation inhibitors and NKAPL-targeted delivery systems for combination therapy for NSCLC. This evidence concerns the gene TRIM21 and non-small cell lung carcinoma.